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Abstract
Human immunodeficiency virus type 1 (HIV-1) Tat plays an important role in HIV-associated
neuropathogenesis; the underlying mechanisms are still evolving. We have recently shown that
HIV-1 Tat induces expression of glial fibrillary acidic protein (GFAP), a characteristic of HIV-1
infection of the central nervous system (CNS). We have also shown that the Tat-induced GFAP
expression in astrocytes is regulated by p300, and that deletion of the early growth response 1
(Egr-1) cis-transacting element within the p300 promoter abolishes Tat-induced GFAP expression.
In this study, we further examined the relationship between Tat and Egr-1 in astrocytes. We found
increased Egr-1 protein expression in Tat-expressing human astrocytoma cells and mouse primary
astrocytes. Using the Egr-1 promoter-driven firefly luciferase reporter gene assay and the site-
directed mutagenesis, we demonstrated that Tat increased Egr-1 expression by transactivating the
Egr-1 promoter and involving specific serum response elements (SRE) within the promoter.
Consistent with these data, we showed that Tat transactivation of the Egr-1 promoter was
abrogated when astrocytes were cultured in serum-reduced media. Taken together, these results
reveal that Tat directly transactivates Egr-1 expression and suggest that Tat interaction with Egr-1
is probably one of the very upstream molecular events that initiate Tat-induced astrocyte
dysfunction and subsequent Tat neurotoxicity.
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Introduction
Infection of the central nervous system (CNS) by HIV-1 often causes neurological disorders
such as dementia in AIDS patients (Price et al, 1988). The main neuropathologies are
astrocytosis and cerebral atrophy in the early stage of infection, and formation of myelin
pallor, multinucleated giant cells, neuron degeneration, and an abnormal blood-brain barrier
in the later stage of the disease (Bell et al, 2006; Brew, 2009; Cohen and Gongvatana, 2009;
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Del Valle and Pina-Oviedo, 2006; Ellis et al, 2007; Sacktor, 2002). In the era of highly
active anti-retroviral therapy, a mild form of neurological disorder called mild cognitive and
motor disorder has become more prevalent among HIV-infected subjects (Brew, 2009;
Cohen and Gongvatana, 2009; Sacktor, 2002). In the brain, the primary cell targets for HIV
infection are macrophages/microglia and, to a lesser extent, astrocytes (Gorry et al, 1998;
Lee et al, 1993; Liu et al, 2004; Saito et al, 1994; Schweighardt and Atwood, 2001;
Tornatore et al, 1994). However, neurons that are mostly affected in the brain of HIV-
infected individuals are rarely infected. Therefore, a number of indirect mechanisms have
been proposed for HIV-associated neuropathogenesis. In general, these indirect mechanisms
can be grouped into three main categories: improper immune activation, soluble factors of
both viral and host origins, and astrocyte dysfunction.
Among the soluble factors is the HIV-1 Tat protein. Tat is present in the serum and the brain
of HIV-infected individuals (Bratanich et al, 1998; Cupp et al, 1993; Kolson et al, 1993;
Parmentier et al, 1992; Westendorp et al, 1995a; Xiao et al, 2000b). It causes direct
neurotoxicity by various mechanisms including neuroexcitation, Ca2+ flux, and oxidative
stress (Chen et al, 1997; Cheng et al, 1998; Conant et al, 1998; Hofman et al, 1999; Hofman
et al, 1994; Hofman et al, 1993; Jones et al, 1998; Liu et al, 2000a; Sabatier et al, 1991;
Westendorp et al, 1995b; Zidovetzki et al, 1998; Zocchi et al, 1998). It can also affect
neuronal proliferation and differentiation through interaction with cell cycle-related proteins
(Milani et al, 1993; Zhou and He, 2004a; Zhou et al, 2004). Moreover, Tat could also
specifically affect neuronal functions through its uptake, followed by altering neuronal gene
expression (Bonifaci et al, 1995; Frankel and Pabo, 1988; Green et al, 1989; Liu et al,
2000a; Mann and Frankel, 1991; Viscidi et al, 1989; Westendorp et al, 1995a; Xiao et al,
2000a). Furthermore, Tat itself possesses the chemoattractant activity and induces excessive
CNS infiltration of neutrophils, macrophages and monocytes, which in turn affect neuron
survival and function (Chen et al, 1997; Cheng et al, 1998; Conant et al, 1998; Jones et al,
1998; Kim et al, 2003; Liu et al, 2000b).
More evidence has begun to emerge to indicate that Tat interaction with astrocytes also
contributes to Tat neurotoxicity. Tat alters astrocytes and neurons to form aggregates and the
neuritic processes to coalesce into fascicles in cultures (Kolson et al, 1993). Tat induces
MCP-1 expression in and release from astrocytes, and MCP-1 level in the cerebrospinal
fluid correlates with AIDS dementia (Conant et al, 1998). In addition to MCP-1, Tat also
induces expression of several other cytokines and chemokines, including IL-1β, IL-6,
Rantes, and CXCL10 (El-Hage et al, 2005; Nath et al, 1999; Williams et al, 2009). We have
recently shown that Tat enhances GFAP expression in astrocytes and impairs astrocyte
function and that GFAP dysregulation is directly involved in Tat neurotoxicity (Zhou and
He, 2004b; Zhou et al, 2004; Zou et al, 2007). Furthermore, we have shown that the
transcriptional co-activator p300 regulates Tat-induced GFAP up-regulation through
transcription factor early growth response 1 (Egr-1) (Zou, et al. 2009, in preparation). In this
study, we aimed to analyze the relationship between Tat and Egr-1 in astrocytes and the
possible roles of Egr-1 in regulation of Tat interaction with astrocytes and Tat neurotoxicity.
Materials and Methods
Cells and cell cultures
293T cells, U373.MG and U87.MG were purchased from American Tissue Culture
Collection (ATCC, Manassas, VA). These cells were maintained in Dulbecco's modified
Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 50 units/ml
penicillin and 50 μg/ml streptomycin in a 37°C, 5% CO2 incubator. Primary astrocytes were
isolated from 18.5 day old embryonic brain tissue of the Tat-inducible transgenic mice
described previously (Zhou et al, 2004). Briefly, the cortex of the mouse embryonic brain
Fan et al. Page 2
J Neuroimmune Pharmacol. Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
tissue was aseptically and mechanically separated and dissociated in Ca2+/Mg2+ free Hanks
balanced salt solution (HBSS) with 0.035% sodium bicarbonate and 1 mM sodium pyruvate
(pH7.4), and then treated with 0.25% trypsin at 37°C for 30 min. Trypsin digestion was
halted by washing cells with Ca2+/Mg2+ free HBSS supplemented with 10% FBS, followed
by low speed centrifugation to remove debris. Cells were suspended and plated at an
appropriate density in F12-K medium (Cellgro, Manassas, VA) containing 10% FBS, 50
units/ml penicillin and 50 μg/ml streptomycin. Culture medium was changed 24 hr
following the initial plating and then every 3-4 days in order to remove non-adherent cells;
primary astrocytes were used after 3-4 passages.
Plasmids
pcDNA3, pGL3-basic and pCMV-βgal were purchased from Clonetech (Mountain View,
CA). pcTat.Myc was previously described (Zhou and He, 2004b). For pEgr-1p-Luc, the full-
length human Egr-1 promoter (about 700 bp) was amplified from the genomic DNA of U87
cells and cloned into pGL3-basic using Mlu I and Xho I to produce pEgr-1p-Luc. pEgr-1p-
Luc was then digested with Sca I to remove 468 bp at the 5′ end of the Egr-1 promoter, the
resulting DNA was ligated to generate the plasmid pEgr-1pΔ468-Luc. Similarly,
pEgr-1pΔ260-Luc was made using Mlu I/Pvu II. pEgr-1pΔEBS-Luc was constructed using a
QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and pEgr-1p-
Luc as the template and primers 5′-GCG ATA GAA CCG CGG CCC GAC TCG CCG
CGG GTC TGG GCT TCC CCA GCC T-3′ and 5′-AGG CTG GGG AAG CCC AGA CCC
GCG GCG AGT CGG GCC GCG GTT CTA TCG C-3′ (Sac II sites in bold).
pEgr-1pΔEBSΔTRE was obtained by digesting pEgr-1pΔEBS-Luc with Sac II, followed by
ligation. All recombinant plasmids were verified by sequencing.
Transfections and Western blot analysis
U373.MG were plated in a 12-well plate at a density of 6 × 104/well or a 6-well plate at a
density of 2 × 105/well and transfected with plasmids using the standard calcium phosphate
precipitation methods. Cells were harvested 24 hr after transfection for RNA analysis and 72
hr after transfection for protein analysis and reporter gene assays. Cells were washed once in
ice-cold phosphate-buffered saline (PBS) and lyzed in a RIPA buffer [50 mM Tris.HCl
pH7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 2 mM
PMSF, and 1× protease inhibitor cocktail (Roche, Indianapolis, IN)] on ice for 20 min to
obtain whole cell lysates. For GFAP, cells were lysed in a Triton buffer [20 mM Tris.HCl
pH7.5, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1× protease inhibitor cocktail
(Roche)] on ice for 20 min. The pellets were then extracted with 4× SDS-PAGE loading
buffer (0.2 M Tris.HCl, pH6.8, 8% SDS, 50 mM EDTA, 40% glycerol, 0.08% bromophenol
blue, and 4% β-mercaptethanol) and heated at 60°C for 30 min, then at 100°C for 10 min,
and then used to determine for GFAP expression. Protein concentration was determined
using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). Cell lysates were subjected
to 10% SDS-PAGE and Western blot analysis with appropriate primary antibodies, HRP-
labeled secondary antibodies and a ECL chemiluminescence kit (Amersham, Piscataway,
NJ). α-GFAP and α-actin antibodies were from Sigma (St. Louis, MO), and α-Egr-1 and α-
Myc antibodies were from Santa Cruz Biotechnologies (Santa Cruz, CA).
RNA isolation and semi-quantitative reverse transcription PCR (RT-PCR)
Total RNA was isolated using a Trizol Reagent kit (Invitrogen, Carlsbad, CA) according to
the manufacturer's instructions. RT-PCR was performed on a PE Thermocycler 9700 (PE
Applied Biosystem, Foster City, CA) using a Titan One Tube RT-PCR kit (Boehringer
Mannheim, Indianapolis, IN) with Tat primers 5′-GTC GGG ATC CTA ATG GAG CCA
GTA GAT CCT-3′ and 5′-TGC TTT GAT AGA GAA ACT TGA TGA GTC-3′, GFAP
primers 5′-AAG CAG ATG AAG CCA CCC TG-3′ and 5′-GTC TGC ACG GGA ATG
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GTG AT-3′, and GAPDH primers 5′-CTC AGT GTA GCC CAG GAT GC-3′ and 5′-ACC
ACC ATG GAG AAG GCT GG-3′. All the reactions were performed with the program of
50°C for 30 min, 94°C for 2 min, followed by 10 cycles of 94°C for 15 sec, 55°C for 1 min
and 72°C for 1 min, and 25 cycles of 94°C for 15 sec, 58°C for 1 min and 72°C for 1min,
then 1 cycle of 72°C for 7 min. The expected sizes for GFAP, Tat and GAPDH
amplification products were 625, 216 and 500 bp, respectively. Control RT-PCR reactions
containing no reverse transcriptase were included to ensure no genomic DNA
contamination.
Preparation of pseudotyped HIV-GFP virus and infection of U373.MG cells
293T cells were transfected with pHIV-GFP plasmid and pHCMV-G plasmid using the
standard calcium phosphate precipitation method. The culture supernatant was collected 48
hr after the medium change, briefly centrifuged to remove cell debris, and used as the virus
stock. U373.MG cells were infected with VSV-G pseudo-typed HIV-GFP viruses in the
presence of 8 μg/ml polybrene at 37°C for 2 hr. The cells were then thoroughly washed with
culture medium to remove unbound viruses and cultured for additional 48 hr. The dosages of
the viruses for infection were titrated for U373.MG to ensure minimal cell death and
maximal infection efficiency.
Reporter gene assays
Cells were harvested in ice-cold PBS and collected by brief centrifugation. Cell lysates were
obtained for the firefly luciferase assay according to the manufacturer's instruction
(Promega, Madison, WI). The luciferase activity was quantitated using an Opticomp
Luminometer (MGM Instruments, Hamden, CT). For β-galactosidase reporter gene assay,
30 μl cell extract was mixed with 3 μl 100× Mg2+ solution (0.1 M MgCl2 and 4.5 M β-
mecaptoethanol, 66 μl 4 mg/ml O-nitrophenyl-β-D-galactopyranoside in 0.1 M sodium
phosphate, pH7.5 and 201 μl 0.1 M sodium phosphate, pH7.5). The mixture was incubated
at 37°C for 30 min, the optical density at 405 nm was determined and expressed as the
relative β-galactosidase activity. The β-galactosidase activity was then used to normalize the
transfection variations for the luciferase reporter gene assay.
Data analysis
All experiment data were analyzed by two-tailed student's t test. A p < 0.05 was considered
to be statistically significant and labeled “*”; a p < 0.01 was considered to be statistically
highly significant and labeled “**”.
Results
Egr-1 up-regulation in Tat-expressing U373.MG, U87.MG and primary astrocytes
Our previous studies suggest that Egr-1 is likely directly involved in Tat-induced p300 and
GFAP expression in astrocytes. Egr-1 gene belongs to a group of early response genes and
regulates expression of a wide spectrum of cellular genes; it functions as a convergence
point for many intracellular signaling cascades. Thus, we examined the relationship between
Tat expression and Egr-1 expression. We first transfected Tat-expressing plasmid into
human astrocytoma cells U373.MG and determined Egr-1 expression by Western blot
analysis. The results showed that Tat expression in these cells was accompanied by
increased Egr-1 protein expression (Fig. 1A). Similar results were obtained in another
widely used human astrocytoma cells U87.MG (Fig. 1B). To further examine the
phenomenon, we isolated primary astrocytes from the brain of inducible and astrocyte-
specific Tat transgenic mice (Kim et al, 2003;Zou et al, 2007). We then cultured these cells
with doxycycline (Dox) for 1, 2, 3, and 4 days. We also included primary astrocytes from
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wild-type C57/BL6 mice, in which the Tat transgenic mice were bred as a control in these
experiments. As shown previously, Tat expression was induced in these primary cells by
Dox over time, as demonstrated by RT-PCR (top panel, Fig. 1C). In parallel, there was
induction of Egr-1 protein expression in these cells (middle panel, Fig. 1C, shown by
arrow). In contrast, Egr-1 expression showed no changes in Dox-treated wild-type primary
astrocytes (Fig. 1D). We next determined whether HIV-1 infection would also lead to
increased Egr-1 expression in astrocytes. To facilitate HIV entry into these cells, we took
advantage of the vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped replication-
defective HIV-GFP reporter virus. U373.MG cells were infected with this virus at different
multiplicities of infection (MOI) as indicated. Cells were then harvested for Western blot
analysis. The results showed that Egr-1 expression was gradually induced at a MOI lower
than 1, and maximized at MOI of 1, and then decreased to the basal level when the MOI
exceeded 1 (Fig. 1E). GFAP expression showed a similar expression kinetics in HIV
infected astrocytes, which further support our previous finding that Egr-1 regulates GFAP
expression (Zou, et al, in preparation). HIV infection was verified by p24 and GFP
expression in these cells. Taken together, these results indicate that Egr-1 is induced in
astrocytes either by Tat expressing alone or by HIV-1 infection.
Up-regulation of the Egr-1 promoter activity in astrocytes by Tat
Next, we wished to determine whether Tat enhanced Egr-1 expression at the transcriptional
level. To address this possibility, we created a firefly luciferase (Luc) reporter gene under
the control of the human Egr-1 promoter pEgr-1p-Luc. U373.MG cells were transfected
with pEgr-1p-Luc and different amounts of Tat-expressing plasmid as indicated. pCMV-
βgal was included in the transfection as a transfection efficiency control for normalization,
while pcDNA3 was added to equalize the total amount of DNA among the transfections.
The cells were harvested for cell lysates for the reporter gene assays as well as protein
expression analysis. The results showed that Tat increased the Egr-1 promoter-driven Luc
reporter gene expression when the input amount of Tat was below 0.2 μg (top panel, Fig. 2).
Further increase of the input amount of Tat led to decreases in the Luc reporter gene
expression, which is likely due to the anti-proliferative effects of Tat on these cells (Zhou
and He, 2004b). In agreement with the reporter gene data, Egr-1 protein expression
exhibited a similar kinetics (bottom panel, Fig. 2). In addition, GFAP protein expression was
in parallel with that of Egr-1. These results suggest that Tat-induced Egr-1 expression likely
results from transactivation of the Egr-1 promoter transcription.
Analysis of the functional elements of the human Egr-1 promoter in response to Tat
expression
To further examine the mechanism of Tat-induced Egr-1 up-regulation, we investigated the
importance of the cis-acting elements of the Egr-1 promoter. There are several putative
DNA binding sites for transcription factors including one Sp1 site, two cAMP response
elements (CRE), one 12-O-tetradecanoyl phorbol 13-acetate response element (TRE), one
Egr-1 binding site (EBS), and five serum response elements (SRE) within the human Egr-1
promoter (Aicher et al, 1999; Schwachtgen et al, 2000). Thus, we first constructed a
deletion mutant Δ468 that was deleted the 468 bp fragment of the Egr-1 promoter at the 5′
end (left panel, Fig. 3) and determined its effects on Tat-induced Egr-1 transactivation. We
then performed similar transfections as above with the reporter plasmid and 0.2 μg Tat
plasmid. Compared to the full-length Egr-1 promoter-driven reporter (FL), Δ468 showed a
significantly lower Luc activity (right panel, Fig. 3). Meanwhile, this deletion gave rise to no
significant difference in the Luc activity between Tat and the cDNA3 control. In addition,
we also constructed Δ260, ΔEBS, and ΔEBSΔTRE, which were deleted the 260 bp fragment
at the 5′ end, the EBS binding site, and both EBS and TRE DNA binding sites, respectively,
and determined their effects on Tat-induced transactivation of the Egr-1 promoter.
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Interestingly, compared to the full-length promoter, all deletion mutants showed a
significant increase in the Luc activity, and the biggest increase was detected in ΔEBS-
transfected cells. On the other hand, none of the mutants had significant changes in the Luc
activity in Tat-expressing cells. Taken together, these results indicate that SRE1/2/3 are
likely involved in Tat-induced Egr-1 transactivation. Moreover, these results also suggest
that the Egr-1 promoter contains positive cis-elements SRE1/2/3 and negative cis-elements
TRE and EBS for its transcriptional control.
Tat-induced Egr-1 up-regulation is modulated by SRE within the Egr-1 promoter
The SRE is the binding site for serum response factor (SRF), a ubiquitous 67 kDa protein
whose binding is essential for response of the promoter to serum stimulation (Treisman,
1992). Thus, to ascertain the role of SRE in Tat-induced Egr-1 expression, we determined
Tat effects on the Egr-1 promoter-driven reporter gene activity in the serum-starved cells.
We transfected U373.MG cells with the full-length Egr-1 promoter-driven Luc reporter with
or without Tat-expressing plasmid and cultured these cells first for 24 hr in the regular 10%
FBS-containing medium and then in medium containing no FBS for 24 hr. Compared to the
cells that were cultured in the regular 10% FBS-containing medium, serum starvation not
only significantly decreased the basal activity of the Egr-1 promoter but also Tat-induced
transactivation of the Egr-1 promoter (Fig. 4). In contrast, serum starvation exhibited little
effects on the activity of the Δ468 Egr-1 promoter. The slightly higher activity of the full-
length Egr-1 promoter and the slightly lower activity of the Δ468 Egr-1 promoter in the
serum starved cells than the activity of the Δ468 Egr-1 promoter in the 10% FBS-cultured
cells are likely due to the presence of the other two SRE at the 3′ end of the Egr-1 promoter.
These results provide further evidence to support that the SRE play important role in
regulating Egr-1 transcription but also Tat-induced Egr-1 transactivation.
Discussion
In this study, we showed that Egr-1 protein level was up-regulated in Tat-expressing human
astrocytoma cell lines and mouse primary astrocytes and HIV-infected astrocytes. We then
showed that Tat-induced Egr-1 up-regulation occurred at the transcriptional level. Moreover,
we showed that SRE within the Egr-1 promoter were important for Tat-induced Egr-1 up-
regulation.
HIV-1 Tat regulates expression of a plethora of cellular genes, including several genes in
astrocytes, as discussed above. In this study, we identified Egr-1 as a Tat positive regulatory
target gene in astrocytes, which functioned upstream of two other Tat positive regulatory
genes p300 and GFAP in these cells. Egr-1 is induced in HIV-infected monocytic and
human CD4+ T lymphocytes (Dron et al, 1999) and astrocytes that were infected with HIV
as shown in this study and other viruses (Cai et al, 2006; Romagnoli et al, 2008). In contrast,
two early studies have shown that HIV-1 Tat blocks nerve growth factor-induced Egr-1
expression in neurons (Darbinian et al, 2008; Darbinian-Sarkissian et al, 2006). The discrete
effects of Tat on Egr-1 expression are likely due to the differences between the target cells,
i.e., among neurons, lymphocytes, and astrocytes. Nevertheless, the current study adds the
Egr-1/p300/GFAP to the increasing number of the Tat target genes and supports the notion
that altered cellular gene expression is an important indirect mechanisms by which Tat
contributes to HIV-associated neuropathologies in the brain.
HIV-1 Tat effects on host gene expression are thought to be mediated through indirect
mechanisms, since it has no DNA-binding activity. Our studies showed that Tat activated
Egr-1 expression at the transcriptional level. The Egr-1 promoter has a number of cis-
regulatory elements including the major SRE regulatory sequences, the SRE 1/2/3 (Aicher et
al, 1999; Herbison et al, 1999). In agreement with these findings, we showed that SRE 1/2/3
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were the major regulator for Egr-1 expression as well as Tat-induced Egr-1 up-regulation.
The SRE activity is highly responsive to a wide range of physiological stimuli and signals,
mostly through various intracellular signaling pathways (Eugenin et al, 2007; Gineitis and
Treisman, 2001; Khachigian and Collins, 1997; Peruzzi, 2006). On the other hand, both
intracellular and extracellular Tat has been linked to intracellular signaling pathways to
regulate cellular gene expression and subsequently cell proliferation and survival (Eugenin
et al, 2007; Gineitis and Treisman, 2001; Khachigian and Collins, 1997; Peruzzi, 2006).
Thus, it is likely that Tat-induced Egr-1 up-regulation results from cross talks with Tat-
elicited intracellular signaling. Nevertheless, the exact mechanisms underlying the Tat-
induced Egr-1 expression remain to be elucidated.
Egr-1, like other members of the immediate early gene family, functions as a convergence
“gateway” for many signaling cascades and controls many biological functions by altering
its target gene expression to couple extracellular signals to long-term responses. A growing
list of genes have been identified to be Egr-1 regulatory targets. These include transcription
factors such as Egr-1, cytokines such as TGF-β and IL-1, chemokines such as MIP-2,
MCP-1, and neuronal genes (James et al, 2004; Petersohn et al, 1995; Treisman, 1992).
Many of these genes clearly play key roles in cell proliferation and differentiation,
pathological settings and neuronal responses such as neuronal plasticity. Interestingly,
several recent studies have directly linked Egr-1 to astrocyte proliferation, glial scar
formation, astrocyte function and neurite outgrowth and survival of neuronal cells (Beck et
al, 2008; Mayer et al, 2009; Mittelbronn et al, 2009; Shin et al, 2009). Thus, based on our
previous studies and the current study, we propose a Egr-1-medited astrocyte transcriptional
cascade for Tat neurotoxicity (Fig. 5). It begins with Egr-1 transactivation by Tat, produced
by direction HIV infection of astrocytes or secreted by HIV-infected macrophages/microglia
and taken up by astrocytes or direct HIV infection of astrocytes. Egr-1 activation leads to
p300 expression, which in turns activate GFAP expression in astrocytes or astrocytosis.
Elucidation of the molecular pathways by which Tat activates Egr-1 expression presents a
new opportunity to further discern the neuroprotective from the neurotoxic functions of
astrocytosis and might lead to new approaches to modulate the time span and severity of
astrocytosis, thus fine-tuning neuronal tissue repair and regeneration in the context of HIV
infection.
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Figure 1. Egr-1 up-regulation in Tat-expressing U373 cells, U87 cells and primary astrocytes
Cells were transiently transfected with pCDNA3 or pcTat.Myc and harvested after 72 h;
Cell lysates of (A) U373 and (B) U87 cells were analyzed for Tat and Egr-1 expression, with
β-actin included as a loading control. Primary astrocytes were prepared from brain-targeted
inducible Tat transgenic mice and cultured in the absence or presence of 5ug/ml doxcycline
(Dox) for up to 3 days (C) then analyzed for Tat and Egr-1 expression. Total RNA was
isolated and subjected to RT-PCR using Tat-specific primers with GAPDH used as a loading
control. As a control, primary astrocytes were also prepared from wild-type C57/BL6 mice,
treated with Dox and analyzed for Egr-1 expression (D). Meanwhile, U373 cells were
infected with increasing amounts of VSV-G pseudotyped HIV-GFP virus and harvested
after 72 h. Cell lysates were analyzed for Egr-1, GFAP, and Tat expression (E), along with
p24 and GFP to ensure infection efficiency. β-actin was included as a loading control. Data
is representative of at least three independent experiments.
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Figure 2. Egr-1 promoter activity and expression of Egr-1 protein increases in the presence of a
specific amount of Tat
U373 cells were transiently transfected with Egr-1 promoter-driven luciferase reporter
plasmid pEgr-1p-Luc or control plasmid pGL3 along with increasing amounts of pcTat.Myc
and harvested 72h post-transfection. Half of the cells were to detect Egr-1 promoter activity
(A) with pCMV-βgal used to normalize for variations in transfection efficiency. The
remaining transfected cells were separated and used for Triton-soluble (TS) and Triton-
insoluble (TIS) fractions and analyzed for Egr-1, GFAP and Tat expression, with β-actin
included as a loading control (B).
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Figure 3. Analysis of the functional elements of the human Egr-1 promoter in response to Tat
expression
The full length human Egr-1 promoter was cloned from the genomic DNA of U87 cells and
inserted into pGL3, and then used to create a panel of Egr-1 promoter mutations (A). Cells
were transiently transfected each pEgr-1p-luc mutant plasmid and either pcTat.Myc or
pcDNA3, then harvested 72h post-transfection. Cell lysates were used to determine
luciferase activity (B), with pCMV-βgal included to normalize the transfection efficiency.
Data is representative of at least three independent experiments.
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Figure 4. Tat-induced Egr-1 up-regulation is modulated by the serum response element during
starvation
U373 cells were transfected with either pEgr-1p-700-luc or pEgr-1p-200-luc along with
pcTat.Myc or pcDNA3. At 16h post-transfection the media was replaced with DMEM
containing reduced concentrations of serum and incubated for additional 48 hr. Cell lysates
were then used to determine luciferase activity, with pCMV-βgal included to normalize the
transfection efficiency. Data is representative of at least three independent experiments.
Fan et al. Page 15
J Neuroimmune Pharmacol. Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. The Egr-1 transcriptional network altered by HIV-1 Tat in astrocytes
HIV-1 Tat protein in astrocytes can be derived from direct HIV infection of these cells
themselves. It can also be from HIV-infected microglia/macrophages, followed by its uptake
by astrocytes. Tat then transactivates Egr-1 expression, which in turn transactivates p300
expression, which in turn transactivates GFAP expression. Activation of GFAP expression
or expression of other target genes of Egr-1 and p300 leads to changes in astrocyte
proliferation, survival and function and as a result, impairs neuronal integrity and survival.
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